Eckert & Ziegler stock (DE0005659700): radiopharma specialist updates investors after 2024 results

Eckert & Ziegler has presented its 2024 figures and outlook, underlining its focus on radiopharmaceutical growth markets. What the latest numbers mean for the stock and why the niche player also attracts attention from US-oriented investors.

Eckert & Ziegler, a German specialist for radiation and radiopharmaceutical technology, recently reported its financial results for 2024 and updated investors on its strategic priorities for the coming years, according to a company statement published on 03/27/2025.Eckert & Ziegler Investor News as of 03/27/2025

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Eckert & Ziegler SE
• Sector/industry: Medical technology, radiopharmaceuticals
• Headquarters/country: Berlin, Germany
• Core markets: Nuclear medicine, medical imaging, industrial and research radiation sources
• Key revenue drivers: Radiopharmaceutical components and radioactive sources for medicine and industry
• Home exchange/listing venue: Xetra (ticker: EUZ)
• Trading currency: EUR

Eckert & Ziegler: core business model

The business model of Eckert & Ziegler is centered on the production and processing of radioactive materials for medical, scientific and industrial applications. The company is known as a supplier of radioactive components that are used in nuclear medicine, for example to diagnose and treat cancer and cardiovascular diseases.Eckert & Ziegler Company Profile as of 02/2025

The company structures its activities into business segments that include medical radioisotopes and industrial products. In nuclear medicine, Eckert & Ziegler manufactures precursors and components that are processed into radiopharmaceuticals by pharmaceutical partners. In the industrial segment, the group supplies radioactive sources used in measuring technology, materials testing and calibration of equipment.

A particular characteristic of the business model is its position as an upstream supplier in complex radiopharmaceutical value chains. Many of the company’s products are not directly visible to end patients or consumers, but are essential for hospitals, imaging centers and pharma companies that rely on reliable supply of isotopes and sealed sources.

Regulation and safety play an important role in the operating model. The handling of radioactive materials requires strict licensing procedures, security measures and quality management. This creates high barriers to entry for new competitors and supports long-term customer relationships, but also means that Eckert & Ziegler must constantly invest in compliance, documentation and facility upgrades.

Main revenue and product drivers for Eckert & Ziegler

According to its 2024 annual figures published on 03/27/2025, Eckert & Ziegler generated a significant share of its revenues with products for nuclear medicine, including isotopes and components used in positron emission tomography and targeted radiopharmaceutical therapies.Eckert & Ziegler Investor News as of 03/27/2025

The medical segment benefits from long-term growth trends: the increasing incidence of cancer and chronic diseases, the spread of modern imaging procedures and the development of new targeted radioligand therapies. These therapies require specific isotopes, and Eckert & Ziegler aims to position itself as a reliable manufacturing partner for pharmaceutical developers that bring such therapies to market.

In the industrial and research segment, key revenue sources include calibration standards and sealed sources used in quality control, level measurement and material testing. While this segment tends to grow more steadily and less dynamically than the medical segment, it can provide recurring revenues based on replacement, maintenance and regulatory requirements.

Another driver is the internationalization of the business. Eckert & Ziegler supplies customers in Europe, North America and Asia, and operates production and service locations in several countries. For US investors, this international footprint is relevant because a portion of revenues is linked to demand from the US health care and research market, which is one of the largest regions for nuclear medicine procedures.

In its outlook for 2025 and subsequent years, the company emphasized investments in capacity expansions for radiopharmaceutical production sites and collaborations with pharmaceutical companies in order to support late-stage clinical programs.Eckert & Ziegler Newsroom as of 04/2025

Conclusion

Eckert & Ziegler positions itself as a specialized supplier in the growing field of nuclear medicine and radiopharmaceuticals, with 2024 results and the 2025 outlook confirming this focus. The company’s upstream role in value chains, combined with regulatory barriers and long-term partnerships, can support stable business development but also requires continuous investment and regulatory compliance. For US-focused investors, the stock offers indirect exposure to radiopharmaceutical growth, including demand from the US health care market, while currency effects, regulatory risks and competition from global isotope suppliers remain important factors to monitor in future reporting periods.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.